Abstract
The platinum-based anticancer drug cis-[PtCl2(NH3)2] (cis-DDP) is one of the most effective drugs available for the treatment of human tumours,1 whereas its trans isomer (trans-DDP) is inactive.2–6 The clinical efficacy of cis-DDP is, however, limited by tumour cell resistance present either in the onset of treatment (intrinsic) or after an initial response (acquired)7 Cis-DDP resistance appears to be mediated by factors which reduce platinum-DNA adduct formation, e.g. reduced intracellular accumulation, increased inactivation by intracellular thiols, increased repair8 or tolerance of platinum-DNA adducts.9
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
P.J. Loehrer and L.H. Einhorn, Cisplatin, Ann. Inter. Med. 100: 704–713 (1984).
T.A. Connors, M.J. Cleare, and K.R. Harrap, Structure-activity relationships of the antitumour platinum coordination complexes, Cancer Treat. Rep. 63: 1499–1502 (1979).
A. Eastman, The formation, isolation, and characterization of DNA adducts produced by anticancer platinum complexes, Pharmacol. Ther. 34: 155–166 (1987).
J. Reedijk, The mechanism of action of platinum antitumor drugs, Pure Appl. Chem. 59: 181–192(1987).
S.L. Bruhn, J.H. Toney, and S.J. Lippard, Biological processing of DNA modified by platinum anticancer drugs, Prog. Inorg. Chem. 38: 477–516 (1990).
M. Sip, A. Schwartz, F. Vovelle, M. Ptak, and M. Leng, Distortion induced in DNA by cis-platinum interstrand adducts, Biochemistry, 31: 2508–2513 (1992).
R.F. Ozols and R.C. Young, Chemotherapy of ovarian cancer, Semin. Oncol. 11: 251–263 (1984).
W. Zhen, C.J. Link, P.M. O’Connor, E. Reed, R. Parker, S.B. Howell, and V. Bohr, Increased gene-specific repair of cisplatin interstrand crosslinks in cisplatin-resistant human ovarian cancer cell lines, mol. Cell. Biol. 12: 3689–3698 (1992).
L.R. Kelland, New platinum antitumor complexes, Crit. Rev. Oncol/Hematol. 15: 191–219 (1993).
K.M. Comess and S.J. Lippard, Molecular aspects of platinum-DNA interactions, in: “Molecular Aspects of Anticancer Drug-DNA Interactions,” Vol. 1, 134–168. S. Neilde and M. Waring, ed., Macmillan Press Ltd., London (1993).
A. Eastman, M.M. Jennerwein, and D.L. Nagel, Characterization of bifunctional adducts produced in DNA by trans-diamminedichloroplatinum(II), Chem. Biol. Interact 67:71–80(1988).
A.P. Pinto and S.J. Lippard, Sequence-dependent termination of in vitro DNA synthesis by cis- and trans-diamminedichloroplatinum(II), Proc. Natl. Acad. Sci. USA, 82: 4616–4619 (1985).
C.A. Lepre, K.G. Strothkamp, and S.J. Lippard, Synthesis and 1H NMR spectroscopic characterization of trans-[Pt(NH3)2d(AGGCCT) N7-A(1), N7-G(3)], Biochemistry, 26: 5651–5657 (1987).
V. Brabec and M. Leng, DNA interstrand cross-links of trans-diamminedichloro-platinum(II) are preferentially formed between guanine and complementary cytosine residues, Proc. Natl. Acad. Sci. USA, 90: 5345–5349 (1993).
N. Farrell, T.T.B. Ha, J.-P. Souchard, F.L. Wimmer, S. Cros, and N.P. Johnsin, Cytostatic trans-platinum(II) complexes. J. Med. Chem. 32: 2240–2241 (1989).
M. Von Beusichem and N. Farrell, Activation of the trans geometry in platinum antitumor complexes. Synthesis, characterization and biological activity of complexes with planar ligands pyridine, N-methylimidazole, thiazole and quinoline. The crystal and molecular structure of trans-dichloro bis(thiazole) platinum(II). Inorg. Chem. 31: 634–639 (1992).
N. Farrell, L.R. Kelland, J.D. Roberts, and M. Von Beusichem, Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans compounds containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action. Cancer Res. 52: 5065–5072 (1992).
M. Coluccia, A. Nassi, F. Loseto, A. Boccarelli, M.A. Mariggiò, D. Giordano, F.P. Intini, P.A. Caputo, and G. Natile, A trans-platinum complex showing higher antitumor activity than the cis congeners. J. Med. Chem. 36: 510–512 (1993).
L.R. Kelland, C.F.J. Barnard, K.J. Mellish, M. Jones, P.M. Goddard, M. Valenti, A. Bryant, B.A. Murrer, and K.R. Harrap, A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity. Cancer Research, 54: 5618–5622 (1994).
M. Coluccia, M.A. Mariggiò, A. Boccarelli, F. Loseto, N. Cardellicchio, P.A. Caputo, F.P. Intini, and G. Natile, Unpublished results.
R. Cini, P.A. Caputo, F.P. Intini, and G.Natile, Mechanistic and stereochemical investigation of iminoethers formed by alcoholysis of coordinated nitriles: X-ray crystal structure of cis- and trans-[bis(1-imino-1-methoxyethane)dichloroplatinum(II)], Inorg. Chem., in press.
M. Coluccia, M. Correale, F.P. Fanizzi, D. Giordano, L. Maresca, M.A. Mariggiò, G. Natile, and M. Tamaro, Mutagenic activity of some platinum complexes: chemical properties and biological activity, Toxicol. Environm. Chem., 8: 1–8 (1984).
A. Eastman and M.A. Barry, Interaction of trans-diammine-dichloroplatinum(II) with DNA: formation of monofunctional adducts and their reaction with glutathione. Biochemistry, 26: 3303–3307 (1987).
G.L. Cohen, J.A. Ledner, W.R. Bauer, H.M. Ushay, C. Caravana, and S.J. Lippard, Sequence dependent binding of cis-dichlorodiammineplatinum(II) to DNA, J. Am. Chem. Soc. 102: 2487–2488 (1980).
R.B. Ciccarelli, M.J. Solomon, A. Varshavsky, and S.J. Lippard, In vivo effects of cis-and trans-diamminedichloroplatinurn(II) on SV40 chromosomes: differential repair, DNA-protein cross-linking, and inhibition of replication. Biochemistry, 24, 7533–7540(1985).
S.W. Johnson, R.P. Perez, A.K. Godwin, A.T. Yeung, L.M. Handel, R.F. Ozols, and T.C. Hamilton, Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem. Pharmacol. 47: 687–697 (1994).
M.A. Lemaire, A. Schwartz, A.R. Rahmouni, and M. Leng, Interstrand crosslinks are preferentially formed at the d(GC) sites in the reaction between cis-diamminedichloroplatinum(II) and DNA. Proc. Natl. Acad. Sci. USA, 88: 1982–1985 (1991).
J. Konopa, J.W. Pawlak, and K. Pawlak, The mode of action of cytotoxic and antitumor 1-nitroacridines. III. In vivo interstrand cross-linking of DNA of mammalian or bacterial cells by 1-nitroacridines. Chem. Biol. Interact. 43: 175–197 (1983).
A. Skladanowski and J. Konopa, Interstrand DNA crosslinking induced by anthracyclines in tumor cells. Biochemical Pharmacology, 47: 2269–2278 (1994).
K. Kohn and C.L. Spears, Stabilization of nitrogen-mustard alkylations and interstrand crosslinks in DNA by alkali. Biochim. Biophys. Acta, 145: 734–741 (1967).
D.C. Gruenert and J.E. Cleaver, Sensitivity of mitomycin C and nitrogen mustard crosslinks to extreme alkaline conditions. Biochem. Biophys. Res. Commun. 123: 549–554 (1984).
J. Konopa, Adriamycin and Daunomycin induce interstrand crosslinks in HeLa S3 cells. Biochem. Biophys. Res. Commun. 110: 819–826 (1983).
P.G. Parson, Dependence on treatment time of melphalan resistance and DNA cross-linking in human melanoma cell lines. Cancer Res. 44: 2773–2778 (1984).
E.P. Geiduschek, “Reversible” DNA. Proc. Natl. Acad. Sci. USA, 47: 950–955 (1961).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media New York
About this chapter
Cite this chapter
Coluccia, M. et al. (1996). Iminoethers as Carrier Ligands: A Novel trans-Platinum Complex Possessing in Vitro and in Vivo Antitumour Activity. In: Pinedo, H.M., Schornagel, J.H. (eds) Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 2. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-0218-4_3
Download citation
DOI: https://doi.org/10.1007/978-1-4899-0218-4_3
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-0220-7
Online ISBN: 978-1-4899-0218-4
eBook Packages: Springer Book Archive